Moody’s invests in alternative data and insights provider MioTech

Moody’s invests in alternative data and insights provider MioTech

Moody’s Corporation, a US-based risk assessment firm, has acquired a minority stake in MioTech, a Hong Kong-based alternative data and insights provider, for an undisclosed price. MioTech caters to the environmental, social, and governance (ESG) and know your customer (KYC) markets in Greater China. According to Moody’s, the investment marks commitment to offering the evolving […]

Couche-Tard to acquire Circle K HK from Convenience Retail Asia for $360m

Couche-Tard to acquire Circle K HK from Convenience Retail Asia for $360m

Alimentation Couche-Tard, a Canadian convenience store chain, has agreed to acquire Convenience Retail Asia (BVI) (Circle K HK) for HK$2.79 billion (nearly $360 million) from Convenience Retail Asia, a Hong Kong retailer. Circle K HK is the operator of a network of Circle K-licensed convenience stores. The network includes 340 company-operated sites across Hong Kong […]

HKBU-led researchers develop EBV drug for nasopharyngeal cancer

HKBU-led researchers develop EBV drug for nasopharyngeal cancer

A research team headed by Hong Kong Baptist University (HKBU) claims to have developed a novel anti-Epstein-Barr virus (EBV) drug for the treatment of nasopharyngeal cancer and other EBV-related cancers. The novel anti-viral targeted drug can disrupt a viral protein produced by EBV selectively, thereby resulting in shrinkage of tumors caused by the human herpesvirus […]

Hong Kong reinsurer Peak Re to acquire ILS asset manager Lutece

Hong Kong reinsurer Peak Re to acquire ILS asset manager Lutece

Peak Re acquisition of Lutece : Peak Reinsurance (Peak Re), a Hong Kong-based reinsurance company, has signed a deal to acquire Bermuda-based insurance-linked securities (ILS) asset manager Lutece and its subsidiary Lutece Investment Management. Financial terms of the deal were not disclosed by the parties. Established about three years ago, Lutece is focused on generating […]

InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal

InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal

In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta Pharmaceuticals Co., Ltd. to co-develop the promising lung cancer drug D-0316. Under this agreement, InventisBio has out-licensed the rights to D-0316 in China, Hong Kong, and Taiwan to Betta Pharmaceuticals Co., Ltd. in a deal valued at […]